Lakefront Biotherapeutics (LKFT) Inventory (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Inventory for 13 consecutive years, with $20.1 million the latest figure, recorded in Q1 2026.

• Quarterly Inventory fell 54.06% year-over-year to $20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.1 million (down 54.06% YoY) and the FY2025 annual result came in at $25.6 million, down 56.06% from the prior year.
• Inventory fell to $20.1 million in Q1 2026 per LKFT's latest filing, from $25.6 million in the prior quarter.
• Over the last five years, Inventory for LKFT reached as high as $91.7 million in Q1 2024 and fell as low as $20.1 million in Q1 2026.
• A 5-year average of $51.2 million and a median of $58.3 million in 2024 frame the typical range for Inventory.
• Annual changes were most pronounced in 2023 — Inventory surged 181.39% — and 2025, when it sank 65.0%.
• Year by year, Inventory stood at $60.2 million in 2022, then jumped by 39.78% to $84.2 million in 2023, then sank by 30.8% to $58.3 million in 2024, then slumped by 56.06% to $25.6 million in 2025, then slipped by 21.34% to $20.1 million in 2026.
• According to Business Quant data, Inventory over the past three periods registered $20.1 million, $25.6 million, and $26.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.